<DOC>
	<DOCNO>NCT01725087</DOCNO>
	<brief_summary>The purpose trial evaluate safety efficacy daily orally administer GRT6005 total 3 fix dos compare placebo subject moderate severe chronic Low Back Pain ( LBP ) . The study include maximum 21 day screen period follow 2-week titration period 12-week maintenance double-blind treatment period 10-14 day safety follow period . Patients eligible double-blind treatment period randomize one follow treatment group : GRT6005 low-dose , GRT6005 medium dose , GRT6005 high-dose , Tapentadol placebo .</brief_summary>
	<brief_title>Efficacy Safety GRT6005 Patients With Chronic Low Back Pain .</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<criteria>Chronic Low Back Pain nonmalignant origin present least 3 month . Signed informed consent . Pain intensity score 5 great 11point numeric rating scale ( 0 indicate `` pain '' 10 indicate `` bad imagine '' ) . On stable analgesic medication ( nonopioid and/or opioid medication ) chronic low back pain regular intake least 3 month dissatisfy current analgesic treatment . Female subject pregnant breastfeeding . Presence risk factor Torsade de Pointes . Any clinically significant disease laboratory finding may affect efficacy safety assessment may compromise safety trial participation , e.g. , significant unstable cardiac , vascular , pulmonary , gastrointestinal , endocrine , metabolic , neurological , psychiatric disorder . History acute hepatitis within past 3 month chronic hepatitis positive result antihepatitis A antibody , hepatitis B surface antigen , antihepatitis C antibody . History human immunodeficiency virus ( HIV ) infection . History seizure disorder . Chronic low back pain potentially associate specific spinal cause . Surgery painful procedure within 3 month enrollment . Conditions contribute confound assessment pain . Subjects impaired renal function . Subjects impaired hepatic functionality . Neuromodulation . Cancer . Clinically relevant history hypersensitivity , allergy contraindication Investigational Medicinal Products ' excipients , paracetamol/acetaminophen , tapentadol Hydrochloride , opioid analgesic ( excipients ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>